Sermorelin
$156.00Sermorelin is the original GHRH (1-29) analog, studied for pulsatile growth hormone release and the GH/IGF-1 axis. See mechanism, comparisons to CJC-1295, and specifications.
Showing 33–45 of 45 results

Sermorelin is the original GHRH (1-29) analog, studied for pulsatile growth hormone release and the GH/IGF-1 axis. See mechanism, comparisons to CJC-1295, and specifications.

SLU-PP-332 is a selective pan-ERR (estrogen-related receptor) agonist studied for mitochondrial biogenesis, oxidative metabolism, and exercise-mimetic endpoints. See mechanism and specifications.

SNAP-8 (acetyl octapeptide-3) is a SNAP-25 C-terminal analog studied for topical SNARE-complex competition and expression-line cosmetic research. See mechanism and specifications.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied for cardiolipin binding, electron-transport-chain stabilization, and ROS reduction endpoints. See mechanism and specifications.

TB-500 is the synthetic N-terminal fragment of Thymosin Beta-4, studied for actin regulation, cell migration, and tissue repair. See mechanism, BPC-157 pairing, and specifications.

Tesamorelin is a stabilized GHRH analog (trans-3-hexenoyl modified) studied for visceral fat and IGF-1 endpoints. See mechanism, comparisons to Sermorelin/Ipamorelin, and specifications.

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid immunomodulatory peptide studied for T-cell maturation and innate immunity. See mechanism, comparisons, and specifications.

Tirzepatide is the dual GLP-1/GIP research peptide. See mechanism, how it compares to semaglutide and retatrutide, and full specifications. 10mg and 60mg vials.

VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide studied for anti-inflammatory signaling, vasodilation, and neuroimmune regulation. See mechanism and specifications.

WWP-3X (Reta) – research-grade lyophilized triple-agonist peptide (GLP-1, GIP, glucagon receptors). Specifications, purity, aliases, and storage information for laboratory research use only.

WWP-4X (Survo) (BI 456906) is a once-weekly glucagon / GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. See mechanism, comparisons, and specifications. 10mg.

WWP-5X (Cagri) is a long-acting amylin analog developed by Novo Nordisk, studied alongside and paired with semaglutide (CagriSema). See mechanism, comparisons, and specifications. 5mg and 10mg.

WWP-6X (Cagri/Sema) is the co-formulated amylin + GLP-1 combination (cagrilintide / semaglutide) developed by Novo Nordisk. See mechanism, REDEFINE trial context, and specifications. 5/5mg blend.
